Rising Demand and Costs for Weight Loss Drugs Spark National Concern

Prescription fills for weight loss drugs Zepbound and Wegovy more than doubled in 2024, despite limited insurance coverage and high costs, according to GoodRx. These drugs, GLP-1 and GIP agonists, are in high demand for their appetite-suppressing effects. Zepbound, new to the market, saw a 300% increase in fills, while Wegovy's fills rose over 100%. Insurance coverage remains limited, with many patients facing high out-of-pocket expenses. GoodRx highlights significant overspending by consumers not using available savings options.